Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulranumab monotherapy for osteoarthritis of the hip or knee
2014-002598-13Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hip osteoarthritis and knee osteoarthritis (OA) comparing Fulranumab with Placebo (2 arms). Primary endpoints: Change from baseline to Week 16 in WOMAC pain subscale score, Change from baseline to Week 16 in WOMAC physical function subscale score and 1 more. Started Mar 2015; status: completed.
02
Drugs
fulranumab
03
Conditions
hip osteoarthritisknee osteoarthritis (OA)
Beyond the preview
Go deeper on 2014-002598-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002598-13.